Reduced doses of SHP2 inhibitors might produce effects that resemble SHP2 depletion in the tumor cells, consistent with the differences between conventional versus judicious doses of angiogenic inhibitors producing regression versus normalization of tumor vessels (81). This evidence concerns the gene PTPN11 and neoplasm.